| 1. |
The above audited Quarterly Results as reviewed by the Audit Committee have been taken on record by the Board at its meeting
held on June 27, 2006. |
| 2. |
Investor complaints pending at the beginning of the fourth quarter: Nil, received: 110, resolved: 110 and lying unresolved at the end of the quarter: Nil. |
| 3. |
The consolidated Quarterly Results include the results of subsidiary companies and joint venture companies as per Accounting Standard 21& 27. |
| 4. |
The
Board recommends dividend @10%on the equity share capital of the Company i.e Rs.0.50 per share subject to approval of members. |
| 5. |
Keeping
in view the Company's business model of vertical integration, the management reviewed the reporting of its financial results under one segment and accordingly the Company reported its entire results under one segment viz. 'Pharmaceutical Products'. |
| 6. |
F.O.B
value of exports is Rs.8163.3 Millions ( previous year Rs.5546.2 Millions). |
| 7. |
With regard to audit qualification
a. On withdrawl from capital reserve, it is explained that a part of consideration of Rs.300 millions, intially recognised on entering in to JV as capital reserve, has since been withdrawn on termination of JV agreement. This has no impact on the profit
for the year as per report of Auditors.b. On no provision for diminution in the value of certain investments, it is to explain that the
Company has made certain strategic investments in manufacturing subsidiaries for vertical integration. Considering nature of industry and gestation period involved, the diminution is of temporary nature and does not require provision in the opinion
of the management. |
| 8. |
Figures have been regrouped wherever necessary. |
